Sign in
4

Changes in Ownership

Sionna Therapeutics, Inc. Filed Acc 0001704336-25-000008

President & CEO sold 99,800 shares at an average $36.26 ($3,618,560)

  • President & CEO acquired 99,800 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Cloonan Michael · President & CEO

Table I: Non-derivative

8 lines
Date Transaction Shares Price Value Owned after D/I
2025-10-21 Exercise or conversion : show line 1 in the form 10b5-1 +13,324 $6.11 $81,410 560,667 D
2025-10-21 Sale : show line 2 in the form 10b5-1 −13,324 $34.44 $458,879 547,343 D
2025-10-21 Exercise or conversion : show line 3 in the form 10b5-1 +30,049 $6.11 $183,599 577,392 D
2025-10-21 Sale : show line 4 in the form 10b5-1 −30,049 $35.63 $1,070,646 547,343 D
2025-10-21 Exercise or conversion : show line 5 in the form 10b5-1 +22,895 $6.11 $139,888 570,238 D
2025-10-21 Sale : show line 6 in the form 10b5-1 −22,895 $36.60 $837,957 547,343 D
2025-10-21 Exercise or conversion : show line 7 in the form 10b5-1 +33,532 $6.11 $204,881 580,875 D
2025-10-21 Sale : show line 8 in the form 10b5-1 −33,532 $37.31 $1,251,079 547,343 D
Open-market sales · 99,800 sh · avg $36.26 · $3,618,560

Table II: Derivative

4 lines
Date Transaction Shares Owned after D/I
2025-10-21 Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −13,324 139,618 D
2025-10-21 Exercise or conversion : show line 10 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −30,049 109,569 D
2025-10-21 Exercise or conversion : show line 11 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −22,895 86,674 D
2025-10-21 Exercise or conversion : show line 12 in the form 10b5-1 Non-Qualified Stock Option (right to buy) −33,532 53,142 D
Loading xslF345X05/edgardoc.xml…